Previous 10 | Next 10 |
Summary Invitae announces debt transaction to refinance 2024 notes. Q4 results decent as ongoing restructuring continues. 2023 guidance could have been better. After the bell on Tuesday, we received fourth quarter results from genetics company Invitae ( NVTA ). Sha...
Gainers: Reata Pharmaceuticals ( RETA ) +176% . OncoSec Medical ( ONCS ) +118% . Sarepta Therapeutics ( SRPT ) +24% . PetIQ ( PETQ ) +17% . Amphastar Pharmaceuticals ( AMPH ) +15% . Losers: Novavax ( NVAX ) -24% . ...
Summary 23andMe has made many strategic acquisitions that have helped the company expand and grow. The genomics industry as a whole is expected to have rapid growth in the future due to the convenience of testing kits as well as the decreased prices. ME stock has invested a lot into...
Image source: The Motley Fool. Invitae (NYSE: NVTA) Q4 2022 Earnings Call Feb 28, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Invitae (NVTA) Q4 2022 Earnings Call Transcript
Invitae Corporation (NVTA) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Hoki Luk - Investor Relations Ken Knight - President and Chief Executive Officer Roxi Wen - Chief Financial Officer Conference Call Participants Ga...
Invitae ( NYSE: NVTA ) said Tuesday it signed certain exchange and financing agreements with a fund managed by Deerfield Management Company and other investors. Shares -2.1% at $2.10 after hours. Through privately negotiated agreements, the company intends to exchange abo...
Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance PR Newswire – In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations – – Participating holder...
Invitae press release ( NYSE: NVTA ): Q4 Non-GAAP EPS of -$0.34 beats by $0.19 . Revenue of $122.45M (-2.9% Y/Y) beats by $1.47M . Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding. Repaid...
Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates PR Newswire – Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to fo...
Invitae ( NYSE: NVTA ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close. The consensus EPS Estimate is -$0.53 (+34.6% Y/Y) and the consensus Revenue Estimate is $120.98M (-4.1% Y/Y). Over the last 2 years, NVTA has beaten EPS estimat...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...